Vice President, Corporate Communications
Carla Taub serves as Vice President, Corporate Communications for Avenzo Therapeutics, responsible for external/internal communications, community relations and administrative activities. She has more than 20 years of communications experience in not-for-profit and public organizations. Mrs. Taub recently served as Senior Director, Corporate Communications for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in August 2022.
Prior to Turning Point Therapeutics, Mrs. Taub was Director of Corporate Communications at Halozyme, where she was responsible for corporate communications, community relations and culture initiatives. Prior to Turning Point Therapeutics, she led internal communications for Hologic, Inc. and Gen-Probe Incorporated, which was acquired by Hologic in 2012.
Mrs. Taub has a B.A. in English from Christian Brothers University in Memphis, Tenn.